J&J's business is so well-diversified that occasional challenges -- like generic competition for its top drugs, product recalls, and lawsuits -- can't meaningfully curb its long-term growth.Wall Street expects its revenue to rise 6% this year, but higher fulfillment and supply chain costs -- along with sales of lower-margin essentials -- could cause its earnings to decline 22%.